New Therapeutic Options for Challenging Hematologic Diseases
May 30, 2008, Chicago, IL
1.5 AMA PRA Category 1 Credits™
Release Date: June 11, 2008
Expiration Date: June 11, 2009
Lecture Overview
Description
There were no approved therapies for myelodysplastic syndromes prior to 2004, but recent advances reveal a number of newer options, including those that extend survival of patients with this disease. The New Therapeutic Options for Challenging Hematologic Diseases symposium will critically examine new data on several approved and investigational novel agents and address issues pertinent to the care of patients with myelodysplastic syndromes or acute myeloid leukemia, such as the role of the International Prognostic Scoring System. Therapeutic options for benign hematologic disorders are also expanding, and the availability of a biologic therapy for patients with paroxysmal nocturnal hemoglobinuria might impact the natural history of this disease. Physicians who attend this program will be able to integrate novel therapies into clinical practice and anticipate the use of investigational therapies for appropriate patients.
Target Audience
This educational program is directed toward medical oncologists and hematologists. Fellows, oncology nurses, physician assistants, and pharmacists interested in the treatment of cancer are also invited to participate.
Learning Objectives
Upon completion of this educational activity, you should be able to:
- Describe the natural history, supportive treatments, and diagnosis of paroxysmal nocturnal hemoglobinuria
- Compare the clinical value of the traditional International Prognostic Scoring System to cytogenetic analysis in prognostication and treatment decision making in myelodysplastic syndromes
- Evaluate the activity of nucleoside analogues in patients with high-risk myelodysplastic syndromes and compare the survival times yielded by those agents to those yielded by best supportive care or chemotherapy
- Assess the impact of DNA-hypomethylating agents on transfusion dependence in patients with myelodysplastic syndromes or acute myeloid leukemia
- Describe novel therapeutic agents, including FTI, mTOR inhibitors, histone deacetylase inhibitors, and signal transduction–targeted therapies, that are in clinical evaluation in myelodysplastic syndromes and acute myeloid leukemia
- Evaluate histone deacetylase inhibitors that have activity either as single agents or combined with approved therapies in acute myeloid leukemia and myelodysplastic syndromes
- Evaluate the efficacy and toxicity of agents inhibiting the complement cascade in paroxysmal nocturnal hemoglobinuria, including effects on hemolysis, quality of life, thromboembolic complications, and transfusion dependence
- Assess the impact of the formulation of DNA-hypomethylating agents on efficacy, feasibility, quality of life, and adverse effects in high-risk myelodysplastic syndromes
Instructions for Participation
To view the streaming Flash Video lectures, click the "View Flash Presentation" link. The latest version of Flash Player is recommended to view the Flash video.
Click here to download Flash Player >>
To download Podcast-ready movies, click "Download Video Podcast," and select "Save target as..." The latest version of Quicktime is recommended to view these movies.
Click here to download Quicktime >>
Complete the evaluation, pretest, and posttest by June 11, 2009 to receive your certificate of credit online.
Please scroll to the bottom and accept the CME Activity Terms in order to continue:
Disclosure Policy It is the policy of Physicians Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity. These persons involved in the influence or control of content for New Therapeutic Options for Challenging Hematologic Diseases symposium have disclosed the following relationships with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually. Daniel J. DeAngelo, MD, PhD Speakers Bureau Bristol-Myers Squibb Company; Celgene Corporation; Enzon Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pharmion Corporation Board of Directors/Other Leadership Position Kanisa Pharmaceuticals, Inc.; Pharmion Corporation Research Funding Celgene Corporation Guillermo Garcia-Manero, MD Research Funding Merck & Co., Inc.; Pharmion Corporation Speakers Bureau MGI PHARMA, Pharmion Corporation Anita Hill, MBChB Other Remuneration Alexion Pharmaceuticals, Inc. Alan List, MD Paid Consultant/Advisory Board Celgene Corporation, Pharmion Corporation Speakers Bureau Celgene Corporation, Pharmion Corporation This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings. Software RequirementsThe Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser. If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About. PC Users If you need to upgrade your Web browser, follow one of the links listed below: Microsoft Internet Explorer Downloads (Outside Source) Mozilla Firefox Product Page (Outside Source) Adobe Flash Player 9 (Outside Source) ITunes for Podcast (Outside Source) Adobe Acrobat Reader (Outside Source) Macintosh Users Compatible Web browsers include Firefox (Outside Source) Apple Safari (Outside Source). Adobe Flash Player 9 (Outside Source) ITunes for Podcast (Outside Source) Adobe Acrobat Reader (Outside Source) Disclaimer The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the faculty and Physicians Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. Please consult full prescribing information for any drugs or procedures discussed within. Privacy Policy Physicians Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045. All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher. ©Copyright 2008 by Physicians Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher. All correspondence should be directed to: Editor, New Therapeutic Options for Challenging Hematologic Diseases Physicians' Education Resource 3500 Maple Ave. Suite 700 Dallas, TX 75219 Phone: (214) 367-3456 Fax: (214) 367-3304 E-mail: editor@pergrouplp.com
